UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Annals of oncology, 2019-08, Vol.30 (8), p.1279-1288

2019

Volltextzugriff (PDF)

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Annals of oncology, 2017-11, Vol.28 (11), p.2768-2772

2017

Volltextzugriff (PDF)

ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer: Results of a Prospective Open-label Clinical Trial

Geburtshilfe und Frauenheilkunde, 2015-09, Vol.75 (9), p.935-940

2015

Volltextzugriff (PDF)

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

Breast cancer research and treatment, 2019-06, Vol.175 (2), p.389-399

2019

Volltextzugriff (PDF)

Abemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET)

Annals of oncology, 2018-10, Vol.29, p.viii106-viii106

2018

Volltextzugriff (PDF)

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

The New England journal of medicine, 2016-11, Vol.375 (18), p.1738-1748

2016

Volltextzugriff (PDF)

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Annals of oncology, 2018-10, Vol.29, p.viii703-viii703

2018

Volltextzugriff (PDF)

Effect of deviation from the mid‐sagittal plane on the measurement of fetal nuchal translucency

Ultrasound in obstetrics & gynecology, 2010-05, Vol.35 (5), p.525-529

2010

Volltextzugriff (PDF)

Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer

Journal of cancer research and clinical oncology, 2013-11, Vol.139 (11), p.1909-1916

2013

Volltextzugriff (PDF)

CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary

Journal of cancer research and clinical oncology, 2013-04, Vol.139 (4), p.551-556

2013

Volltextzugriff (PDF)

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial

Gynecologic oncology, 2017-08, Vol.146 (2), p.279-284

2017

Volltextzugriff (PDF)

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Annals of oncology, 2023-06, Vol.34 (6), p.531-542

2023

Volltextzugriff (PDF)

Chirurgische Therapie der peritonealen Metastasierung in Abhängigkeit von Tumorentität, -stadium und -charakteristik(a)

Zentralblatt für Chirurgie, 2016-08, Vol.141 (4), p.415-420

2016

Volltextzugriff (PDF)

Nodal status—its impact on prognosis in advanced ovarian cancer

Journal of cancer research and clinical oncology, 2012-02, Vol.138 (2), p.261-267

2012

Volltextzugriff (PDF)

Trastuzumab Administration in Patients with Metastatic Breast Cancer – Experience of a Large University Breast Center

Geburtshilfe und Frauenheilkunde, 2014-06, Vol.74 (6), p.563-568

2014

Volltextzugriff (PDF)

Dermatologische Nebenwirkungen der Zytostatika

Aktuelle Dermatologie, 2015-03, Vol.41 (3), p.104-109

2015

Volltextzugriff (PDF)

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study

Breast (Edinburgh), 2019-06, Vol.45, p.22-28

2019

Volltextzugriff (PDF)

Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients

Annals of oncology, 2019-05, Vol.30, p.iii67-iii67

2019

Volltextzugriff (PDF)

169 PazoDoble – Pazopanib vs. Pazopanib plus Gemcitabine in relapsed or metastatic uterine leiomyosarcomas or uterine carcinosacomas

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A153-A154

2021

Volltextzugriff (PDF)

Thyroid disorders during pregnancy--important for the mother and the fetus

Deutsche medizinische Wochenschrift (1946), 2009-01, Vol.134 (3), p.87

Grischke, E-M

2009

Volltextzugriff (PDF)

Electrochemotherapy for breast cancer - results from the INSPECT database

Annals of oncology, 2016-10, Vol.27, p.vi86-vi86

2016

Volltextzugriff (PDF)

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita

Annals of oncology, 2016-10, Vol.27, p.vi85-vi85

2016

Volltextzugriff (PDF)

1 – 25 von 263

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(213)
Mit Volltextzugriff
(182)

Publikationsform

Sprache

Deutsch
(152)
Englisch
(113)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(73)
Female
(68)
Life Sciences & Biomedicine
(47)
Science & Technology
(47)
Adult
(41)
Pregnancy
(30)
Oncology
(27)
Middle Aged
(24)
Aged
(19)
Obstetrics & Gynecology
(17)
Breast Cancer
(16)
Prognosis
(16)
Infant, Newborn
(15)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Risk Factors
(12)
Follow-Up Studies
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)
Breast Neoplasms - Pathology
(10)
Medicine
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer: Results of a Prospective Open-label Clinical Trial

Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008–2019)

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

Abemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET)

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Effect of deviation from the mid‐sagittal plane on the measurement of fetal nuchal translucency

Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer

CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Chirurgische Therapie der peritonealen Metastasierung in Abhängigkeit von Tumorentität, -stadium und -charakteristik(a)

Nodal status—its impact on prognosis in advanced ovarian cancer

Trastuzumab Administration in Patients with Metastatic Breast Cancer – Experience of a Large University Breast Center

Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288]

Dermatologische Nebenwirkungen der Zytostatika

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study

Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients

169 PazoDoble – Pazopanib vs. Pazopanib plus Gemcitabine in relapsed or metastatic uterine leiomyosarcomas or uterine carcinosacomas

Thyroid disorders during pregnancy--important for the mother and the fetus

Electrochemotherapy for breast cancer - results from the INSPECT database

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita

Suchergebnisse filtern